A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FN-1501 (Primary)
Indications Acute myeloid leukaemia; Solid tumours
Focus Adverse reactions; First in man
Sponsors Shanghai Fosun Pharmaceutical

Most Recent Events

11 Jul 2022 Status changed from active, no longer recruiting to discontinued.
07 Jun 2022 Results (n=47; Data cut off: Dec 3, 2021) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
03 Jun 2022 Planned End Date changed from 11 Apr 2022 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight